Fendiline

Fendiline is a nonselective calcium channel blocker and coronary vasodilator, originally developed for its anti-anginal and antiarrhythmic properties in the management of coronary heart disease.^[1][2][3]

Fendiline

Clinical data
ATC code	C08EA01 (WHO)
Identifiers
IUPAC name 3,3-diphenyl-N-(1-phenylethyl)propan-1-amine
CAS Number	13042-18-7 Y
PubChem CID	3336
DrugBank	DB08980 N
ChemSpider	3219 N
UNII	S253D559A8
KEGG	D07185 Y
ChEMBL	ChEMBL254832 N
CompTox Dashboard (EPA)	DTXSID5048473
ECHA InfoCard	100.032.635
Chemical and physical data
Formula	C23H25N
Molar mass	315.460 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(NCCC(c1ccccc1)c2ccccc2)c3ccccc3
InChI InChI=1S/C23H25N/c1-19(20-11-5-2-6-12-20)24-18-17-23(21-13-7-3-8-14-21)22-15-9-4-10-16-22/h2-16,19,23-24H,17-18H2,1H3 N Key:NMKSAYKQLCHXDK-UHFFFAOYSA-N N
NY (what is this?)  (verify)

By inhibiting the influx of calcium ions into cardiac and vascular smooth muscle cells, fendiline promotes vasodilation, particularly of the coronary arteries, thereby increasing blood flow to the heart muscle, alleviating ischemia, and reducing chest pain associated with angina.^[2] Although its clinical use has become limited due to the availability of alternative treatments and its relatively slow onset of action, fendiline remains notable for its long half-life, lack of tolerance development, and demonstrated efficacy in improving exercise tolerance and reducing the frequency of angina attacks in placebo-controlled trials.^[2]